

Freddie Hamdy

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8438926/freddie-hamdy-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

351
papers

18,967
citations

69
h-index

126
g-index

386
ext. papers

22,320
ext. citations

8
avg, IF

5.91
L-index

#	Paper	IF	Citations
351	Metabolic profiling of prostate cancer in skeletal microenvironments identifies G6PD as a key mediator of growth and survival.. <i>Science Advances</i> , 2022 , 8, eabf9096	14.3	1
350	Prostate-Specific Antigen Testing for Prostate Cancer Screening-Is the Message Getting Through?. <i>JAMA Oncology</i> , 2021 ,	13.4	1
349	A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study. <i>Lancet Oncology, The</i> , 2021 , 22, 1618-1631	21.7	10
348	Positron Emission Tomography and Whole-body Magnetic Resonance Imaging for Metastasis-directed Therapy in Hormone-sensitive Oligometastatic Prostate Cancer After Primary Radical Treatment: A Systematic Review. <i>European Urology Oncology</i> , 2021 , 4, 714-730	6.7	3
347	Use of intraoperative fluorescence to enhance robot-assisted radical prostatectomy. <i>Future Oncology</i> , 2021 , 17, 1083-1095	3.6	1
346	Local anaesthetic transperineal (LATP) prostate biopsy using a probe-mounted transperineal access system: a multicentre prospective outcome analysis. <i>BJU International</i> , 2021 , 128, 311-318	5.6	8
345	Identification of a serum biomarker signature associated with metastatic prostate cancer. <i>Proteomics - Clinical Applications</i> , 2021 , 15, e2000025	3.1	1
344	Tumour irradiation combined with vascular-targeted photodynamic therapy enhances antitumour effects in pre-clinical prostate cancer. <i>British Journal of Cancer</i> , 2021 , 125, 534-546	8.7	1
343	A Systematic Review of Prostate Cancer Heterogeneity: Understanding the Clonal Ancestry of Multifocal Disease. <i>European Urology Oncology</i> , 2021 , 4, 358-369	6.7	4
342	Intermediate-risk Prostate Cancer-A Sheep in Wolf's Clothing?. <i>European Urology Oncology</i> , 2021 ,	6.7	
341	Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. <i>Nature Genetics</i> , 2021 , 53, 65-75	36.3	62
340	Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2021 , 24, 532-541	6.2	3
339	Polygenic hazard score is associated with prostate cancer in multi-ethnic populations. <i>Nature Communications</i> , 2021 , 12, 1236	17.4	14
338	A modified Delphi study to develop a practical guide for selecting patients with prostate cancer for active surveillance. <i>BMC Urology</i> , 2021 , 21, 18	2.2	1
337	Placebo comparator group selection and use in surgical trials: the ASPIRE project including expert workshop. <i>Health Technology Assessment</i> , 2021 , 25, 1-52	4.4	0
336	The effect of sample size on polygenic hazard models for prostate cancer. <i>European Journal of Human Genetics</i> , 2020 , 28, 1467-1475	5.3	5
335	Systematic review and meta-analysis of the associations between body mass index, prostate cancer, advanced prostate cancer, and prostate-specific antigen. <i>Cancer Causes and Control</i> , 2020 , 31, 431-449	2.8	24

334	Considerations and methods for placebo controls in surgical trials (ASPIRE guidelines). <i>Lancet, The</i> , 2020 , 395, 828-838	40	26
333	A Genetic Risk Score to Personalize Prostate Cancer Screening, Applied to Population Data. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020 , 29, 1731-1738	4	14
332	Impacts of combining anti-PD-L1 immunotherapy and radiotherapy on the tumour immune microenvironment in a murine prostate cancer model. <i>British Journal of Cancer</i> , 2020 , 123, 1089-1100	8.7	30
331	Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial 2020 , 8,		14
330	Implications of celebrity endorsement of prostate cancer awareness in a tertiary referral unit - the 'Fry-Turnbull' effect. <i>BJU International</i> , 2020 , 125, 484-486	5.6	1
329	Detailed Molecular and Immune Marker Profiling of Archival Prostate Cancer Samples Reveals an Inverse Association between TMPRSS2:ERG Fusion Status and Immune Cell Infiltration. <i>Journal of Molecular Diagnostics</i> , 2020 , 22, 652-669	5.1	2
328	Glutamine deprivation alters the origin and function of cancer cell exosomes. <i>EMBO Journal</i> , 2020 , 39, e103009	13	25
327	Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT. <i>Health Technology Assessment</i> , 2020 , 24, 1-176	4.4	9
326	Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in the Detection of Clinically Significant Prostate Cancer in the Prostate Imaging Reporting and Data System Era: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2020 , 78, 402-414	10.2	65
325	Prostate-Specific Membrane Antigen-Guided Surgery. <i>Journal of Nuclear Medicine</i> , 2020 , 61, 6-12	8.9	16
324	The ProtecT trial: analysis of the patient cohort, baseline risk stratification and disease progression. <i>BJU International</i> , 2020 , 125, 506-514	5.6	14
323	Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received. <i>European Urology</i> , 2020 , 77, 320-330	10.2	50
322	An integrative multi-omics analysis to identify candidate DNA methylation biomarkers related to prostate cancer risk. <i>Nature Communications</i> , 2020 , 11, 3905	17.4	12
321	Outreach and Influence of Surgical Societies' Recommendations on Minimally Invasive Surgery During the COVID-19 Pandemic-An Anonymized International Urologic Expert Inquiry. <i>Urology</i> , 2020 , 145, 73-78	1.6	2
320	The ProtecT randomised trial cost-effectiveness analysis comparing active monitoring, surgery, or radiotherapy for prostate cancer. <i>British Journal of Cancer</i> , 2020 , 123, 1063-1070	8.7	4
319	Strategies adopted by men to deal with uncertainty and anxiety when following an active surveillance/monitoring protocol for localised prostate cancer and implications for care: a longitudinal qualitative study embedded within the ProtecT trial. <i>BMJ Open</i> , 2020 , 10, e036024	3	1
318	Transcriptomic and Functional Screens Reveal MicroRNAs That Modulate Prostate Cancer Metastasis. <i>Frontiers in Oncology</i> , 2020 , 10, 292	5.3	3
317	Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. <i>European Urology</i> , 2019 , 76, 831-842	10.2	78

316	Shared heritability and functional enrichment across six solid cancers. <i>Nature Communications</i> , 2019 , 10, 431	17.4	45
315	Increased EZH2 expression in prostate cancer is associated with metastatic recurrence following external beam radiotherapy. <i>Prostate</i> , 2019 , 79, 1079-1089	4.2	19
314	The associations of anthropometric, behavioural and sociodemographic factors with circulating concentrations of IGF-I, IGF-II, IGFBP-1, IGFBP-2 and IGFBP-3 in a pooled analysis of 16,024 men from 22 studies. <i>International Journal of Cancer</i> , 2019 , 145, 3244-3256	7.5	9
313	Factors associated with trial recruitment, preferences, and treatments received were elucidated in a comprehensive cohort study. <i>Journal of Clinical Epidemiology</i> , 2019 , 113, 200-213	5.7	2
312	Mating induces switch from hormone-dependent to hormone-independent steroid receptor-mediated growth in <i>Drosophila</i> secondary cells. <i>PLoS Biology</i> , 2019 , 17, e3000145	9.7	8
311	Comparison of Prostate Biopsy with or without Prebiopsy Multiparametric Magnetic Resonance Imaging for Prostate Cancer Detection: An Observational Cohort Study. <i>Journal of Urology</i> , 2019 , 201, 510-519	2.5	18
310	Germline DNA Repair Gene Mutations in Young-onset Prostate Cancer Cases in the UK: Evidence for a More Extensive Genetic Panel. <i>European Urology</i> , 2019 , 76, 329-337	10.2	28
309	Effect of green tea and lycopene on the insulin-like growth factor system: the ProDiet randomized controlled trial. <i>European Journal of Cancer Prevention</i> , 2019 , 28, 569-575	2	4
308	A Collaborative Analysis of Individual Participant Data from 19 Prospective Studies Assesses Circulating Vitamin D and Prostate Cancer Risk. <i>Cancer Research</i> , 2019 , 79, 274-285	10.1	17
307	Circulating Metabolic Biomarkers of Screen-Detected Prostate Cancer in the ProtecT Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019 , 28, 208-216	4	9
306	Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2018 , 319, 883-895	27.4	184
305	Estimating the sensitivity of a prostate cancer screening programme for different PSA cut-off levels: A UK case study. <i>Cancer Epidemiology</i> , 2018 , 52, 99-105	2.8	4
304	Value of Intact Prostate Specific Antigen and Human Kallikrein 2 in the 4 Kallikrein Predictive Model: An Individual Patient Data Meta-Analysis. <i>Journal of Urology</i> , 2018 , 199, 1470-1474	2.5	8
303	Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets. <i>Nature Genetics</i> , 2018 , 50, 682-692	36.3	112
302	Does the introduction of prostate multiparametric magnetic resonance imaging into the active surveillance protocol for localized prostate cancer improve patient re-classification?. <i>BJU International</i> , 2018 , 122, 794-800	5.6	19
301	Developing new age-specific prostate-specific antigen thresholds for testing for prostate cancer. <i>Cancer Causes and Control</i> , 2018 , 29, 383-388	2.8	9
300	Supporting prostate cancer survivors in primary care: Findings from a pilot trial of a nurse-led psycho-educational intervention (PROSPECTIV). <i>European Journal of Oncology Nursing</i> , 2018 , 32, 73-81	2.8	12
299	A prospective cohort and extended comprehensive-cohort design provided insights about the generalizability of a pragmatic trial: the ProtecT prostate cancer trial. <i>Journal of Clinical Epidemiology</i> , 2018 , 96, 35-46	5.7	9

298	Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. <i>British Journal of Cancer</i> , 2018 , 118, 266-276	8.7	9
297	Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts. <i>BMJ, The</i> , 2018 , 360, j5757	5.9	85
296	Sprouty2 loss-induced IL6 drives castration-resistant prostate cancer through scavenger receptor B1. <i>EMBO Molecular Medicine</i> , 2018 , 10,	12	13
295	Development of a framework to improve the process of recruitment to randomised controlled trials (RCTs): the SEAR (Screened, Eligible, Approached, Randomised) framework. <i>Trials</i> , 2018 , 19, 50	2.8	30
294	Nuclear IGF1R Interacts with Regulatory Regions of Chromatin to Promote RNA Polymerase II Recruitment and Gene Expression Associated with Advanced Tumor Stage. <i>Cancer Research</i> , 2018 , 78, 3497-3509	10.1	30
293	Population screening for prostate cancer 2018 , 171-182		
292	AA9int: SNP interaction pattern search using non-hierarchical additive model set. <i>Bioinformatics</i> , 2018 , 34, 4141-4150	7.2	3
291	Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. <i>Nature Genetics</i> , 2018 , 50, 928-936	36.3	340
290	Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. <i>Nature Communications</i> , 2018 , 9, 2256	17.4	57
289	Overcoming difficulties with equipoise to enable recruitment to a randomised controlled trial of partial ablation vs radical prostatectomy for unilateral localised prostate cancer. <i>BJU International</i> , 2018 , 122, 970-977	5.6	10
288	Prostatic capsular incision during radical prostatectomy has important oncological implications: a systematic review and meta-analysis. <i>BJU International</i> , 2018 , 124, 554	5.6	6
287	Partial ablation versus radical prostatectomy in intermediate-risk prostate cancer: the PART feasibility RCT. <i>Health Technology Assessment</i> , 2018 , 22, 1-96	4.4	18
286	Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. <i>Journal of Clinical Oncology</i> , 2018 , 36, 414-424	2.2	107
285	Germline variation at 8q24 and prostate cancer risk in men of European ancestry. <i>Nature Communications</i> , 2018 , 9, 4616	17.4	30
284	ProDiet: A Phase II Randomized Placebo-controlled Trial of Green Tea Catechins and Lycopene in Men at Increased Risk of Prostate Cancer. <i>Cancer Prevention Research</i> , 2018 , 11, 687-696	3.2	21
283	10-Year Outcomes in Localized Prostate Cancer. <i>New England Journal of Medicine</i> , 2017 , 376, 180	59.2	12
282	Survival Among Men at High Risk of Disseminated Prostate Cancer Receiving Initial Locally Directed Radical Treatment or Initial Androgen Deprivation Therapy. <i>European Urology</i> , 2017 , 72, 345-351	10.2	12
281	Understanding and Improving Recruitment to Randomised Controlled Trials: Qualitative Research Approaches. <i>European Urology</i> , 2017 , 72, 789-798	10.2	76

280	Appraising the relevance of DNA copy number loss and gain in prostate cancer using whole genome DNA sequence data. <i>PLoS Genetics</i> , 2017 , 13, e1007001	6	20
279	Height, selected genetic markers and prostate cancer risk: results from the PRACTICAL consortium. <i>British Journal of Cancer</i> , 2017 , 117, 734-743	8.7	5
278	Cross-sectional study evaluating data quality of the National Cancer Registration and Analysis Service (NCRAS) prostate cancer registry data using the Cluster randomised trial of PSA testing for Prostate cancer (CAP). <i>BMJ Open</i> , 2017 , 7, e015994	3	7
277	Systematic Review of Studies Reporting Positive Surgical Margins After Bladder Neck Sparing Radical Prostatectomy. <i>Current Urology Reports</i> , 2017 , 18, 99	2.9	17
276	Post-diagnosis serum insulin-like growth factors in relation to dietary and lifestyle changes in the Prostate testing for cancer and Treatment (ProtecT) trial. <i>Cancer Causes and Control</i> , 2017 , 28, 877-888	2.8	2
275	Properties of the 4-Kallikrein Panel Outside the Diagnostic Gray Zone: Meta-Analysis of Patients with Positive Digital Rectal Examination or Prostate Specific Antigen 10 ng/ml and Above. <i>Journal of Urology</i> , 2017 , 197, 607-613	2.5	13
274	Prostate cancer risk related to foods, food groups, macronutrients and micronutrients derived from the UK Dietary Cohort Consortium food diaries. <i>European Journal of Clinical Nutrition</i> , 2017 , 71, 274-283	5.2	20
273	Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT Trial. <i>European Urology</i> , 2017 , 71, 381-388	10.2	25
272	Alcohol consumption and prostate cancer incidence and progression: A Mendelian randomisation study. <i>International Journal of Cancer</i> , 2017 , 140, 75-85	7.5	22
271	Reducing Mortality in the Ageing Patient: Treatment of the Primary Tumour Is Not Necessary. <i>European Urology Focus</i> , 2017 , 3, 328-329	5.1	
270	Prostate-specific antigen (PSA) testing of men in UK general practice: a 10-year longitudinal cohort study. <i>BMJ Open</i> , 2017 , 7, e017729	3	16
269	SNP interaction pattern identifier (SIPI): an intensive search for SNP-SNP interaction patterns. <i>Bioinformatics</i> , 2017 , 33, 822-833	7.2	8
268	Validation of the Hospital Episode Statistics Outpatient Dataset in England. <i>Pharmacoeconomics</i> , 2016 , 34, 161-8	4.4	15
267	10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. <i>New England Journal of Medicine</i> , 2016 , 375, 1415-1424	59.2	1451
266	Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. <i>New England Journal of Medicine</i> , 2016 , 375, 1425-1437	59.2	655
265	Patient-reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life. <i>BJU International</i> , 2016 , 118, 869-879	5.6	38
264	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. <i>Cancer Discovery</i> , 2016 , 6, 1052-67	24.4	104
263	Investigating the prostate specific antigen, body mass index and age relationship: is an age-BMI-adjusted PSA model clinically useful?. <i>Cancer Causes and Control</i> , 2016 , 27, 1465-1474	2.8	14

262	Atlas of prostate cancer heritability in European and African-American men pinpoints tissue-specific regulation. <i>Nature Communications</i> , 2016 , 7, 10979	17.4	37
261	Contemporary accuracy of death certificates for coding prostate cancer as a cause of death: Is reliance on death certification good enough? A comparison with blinded review by an independent cause of death evaluation committee. <i>British Journal of Cancer</i> , 2016 , 115, 90-4	8.7	31
260	Characteristics of men responding to an invitation to undergo testing for prostate cancer as part of a randomised trial. <i>Trials</i> , 2016 , 17, 497	2.8	3
259	Pubertal development and prostate cancer risk: Mendelian randomization study in a population-based cohort. <i>BMC Medicine</i> , 2016 , 14, 66	11.4	29
258	Longitudinal prostate-specific antigen reference ranges: Choosing the underlying model of age-related changes. <i>Statistical Methods in Medical Research</i> , 2016 , 25, 1875-1891	2.3	5
257	Misclassification of outcome in case-control studies: Methods for sensitivity analysis. <i>Statistical Methods in Medical Research</i> , 2016 , 25, 2377-2393	2.3	14
256	Insertion of an SVA-E retrotransposon into the CASP8 gene is associated with protection against prostate cancer. <i>Human Molecular Genetics</i> , 2016 , 25, 1008-18	5.6	18
255	A Meta-analysis of Individual Participant Data Reveals an Association between Circulating Levels of IGF-I and Prostate Cancer Risk. <i>Cancer Research</i> , 2016 , 76, 2288-2300	10.1	85
254	DNA-PKcs and PARP1 Bind to Unresected Stalled DNA Replication Forks Where They Recruit XRCC1 to Mediate Repair. <i>Cancer Research</i> , 2016 , 76, 1078-88	10.1	53
253	Regulation of Dense-Core Granule Replenishment by Autocrine BMP Signalling in <i>Drosophila</i> Secondary Cells. <i>PLoS Genetics</i> , 2016 , 12, e1006366	6	18
252	Altered expression of epithelial-to-mesenchymal transition proteins in extraprostatic prostate cancer. <i>Oncotarget</i> , 2016 , 7, 1107-19	3.3	2
251	Identifying Ureters In Situ Under Fluorescence During Laparoscopic and Open Colorectal Surgery. <i>Annals of Surgery</i> , 2016 , 263, e1-2	7.8	29
250	Prostate-specific antigen patterns in US and European populations: comparison of six diverse cohorts. <i>BJU International</i> , 2016 , 118, 911-918	5.6	5
249	PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. <i>Journal of Medical Genetics</i> , 2016 , 53, 800-811	5.8	121
248	Validating the use of Hospital Episode Statistics data and comparison of costing methodologies for economic evaluation: an end-of-life case study from the Cluster randomised triAl of PSA testing for Prostate cancer (CAP). <i>BMJ Open</i> , 2016 , 6, e011063	3	20
247	Novel biomarkers for the detection of prostate cancer. <i>Journal of Clinical Urology</i> , 2016 , 9, 3-10	0.2	15
246	Circulating Folate and Vitamin B and Risk of Prostate Cancer: A Collaborative Analysis of Individual Participant Data from Six Cohorts Including 6875 Cases and 8104 Controls. <i>European Urology</i> , 2016 , 70, 941-951	10.2	36
245	The PROFILE Feasibility Study: Targeted Screening of Men With a Family History of Prostate Cancer. <i>Oncologist</i> , 2016 , 21, 716-22	5.7	24

244	Assessing the role of insulin-like growth factors and binding proteins in prostate cancer using Mendelian randomization: Genetic variants as instruments for circulating levels. <i>International Journal of Cancer</i> , 2016 , 139, 1520-33	7.5	18
243	Symptoms, unmet needs, psychological well-being and health status in survivors of prostate cancer: implications for redesigning follow-up. <i>BJU International</i> , 2016 , 117, E10-9	5.6	90
242	Prevalence of the HOXB13 G84E germline mutation in British men and correlation with prostate cancer risk, tumour characteristics and clinical outcomes. <i>Annals of Oncology</i> , 2015 , 26, 756-761	10.3	67
241	Variation between specialist urologists in reporting extraprostatic extension after radical prostatectomy. <i>Journal of Clinical Pathology</i> , 2015 , 68, 465-72	3.9	7
240	Standardisation of information submitted to an endpoint committee for cause of death assignment in a cancer screening trial Lessons learnt from CAP (Cluster randomised trial of PSA testing for Prostate cancer). <i>BMC Medical Research Methodology</i> , 2015 , 15, 6	4.7	7
239	Achievements and perspectives in prostate cancer phase 3 trials from genitourinary research groups in Europe: introducing the Prostate Cancer Consortium in Europe. <i>European Urology</i> , 2015 , 67, 904-12	10.2	14
238	Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015 , 24, 1121-9	4	46
237	Role of information in preparing men for transrectal ultrasound guided prostate biopsy: a qualitative study embedded in the ProtecT trial. <i>BMC Health Services Research</i> , 2015 , 15, 80	2.9	10
236	Identification and diagnostic performance of a small RNA within the PCA3 and BMCC1 gene locus that potentially targets mRNA. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015 , 24, 268-75	4	5
235	The effects of height and BMI on prostate cancer incidence and mortality: a Mendelian randomization study in 20,848 cases and 20,214 controls from the PRACTICAL consortium. <i>Cancer Causes and Control</i> , 2015 , 26, 1603-16	2.8	56
234	Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans. <i>Human Molecular Genetics</i> , 2015 , 24, 5589-602	5.6	54
233	Castration radiosensitizes prostate cancer tissue by impairing DNA double-strand break repair. <i>Science Translational Medicine</i> , 2015 , 7, 312re11	17.5	59
232	Gleason drift in the NIHR ProtecT study. <i>Histopathology</i> , 2015 , 66, 438-46	7.3	9
231	Carotenoids, retinol, tocopherols, and prostate cancer risk: pooled analysis of 15 studies. <i>American Journal of Clinical Nutrition</i> , 2015 , 102, 1142-57	7	89
230	Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study. <i>Journal of the National Cancer Institute</i> , 2015 , 107,	9.7	116
229	Genome-wide association study of prostate cancer-specific survival. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015 , 24, 1796-800	4	23
228	Implications of polygenic risk-stratified screening for prostate cancer on overdiagnosis. <i>Genetics in Medicine</i> , 2015 , 17, 789-95	8.1	70
227	Prostate cancer cells home to bone using a novel in vivo model: modulation by the integrin antagonist GLPG0187. <i>International Journal of Cancer</i> , 2015 , 136, 1731-40	7.5	9

226	Establishing nurse-led active surveillance for men with localised prostate cancer: development and formative evaluation of a model of care in the ProtecT trial. <i>BMJ Open</i> , 2015 , 5, e008953	3	15
225	Prediction of individual genetic risk to prostate cancer using a polygenic score. <i>Prostate</i> , 2015 , 75, 1467-74	7.4	43
224	Physical activity, alcohol consumption, BMI and smoking status before and after prostate cancer diagnosis in the ProtecT trial: opportunities for lifestyle modification. <i>International Journal of Cancer</i> , 2015 , 137, 1509-15	7.5	19
223	Associations of vitamin D pathway genes with circulating 25-hydroxyvitamin-D, 1,25-dihydroxyvitamin-D, and prostate cancer: a nested case-control study. <i>Cancer Causes and Control</i> , 2015 , 26, 205-218	2.8	28
222	Systematic Review and Meta-analysis of Factors Determining Change to Radical Treatment in Active Surveillance for Localized Prostate Cancer. <i>European Urology</i> , 2015 , 67, 993-1005	10.2	75
221	Incorporating Known Genetic Variants Does Not Improve the Accuracy of PSA Testing to Identify High Risk Prostate Cancer on Biopsy. <i>PLoS ONE</i> , 2015 , 10, e0136735	3.7	5
220	Development, validation and evaluation of an instrument for active monitoring of men with clinically localised prostate cancer: systematic review, cohort studies and qualitative study. <i>Health Services and Delivery Research</i> , 2015 , 3, 1-138	1.5	3
219	The future of randomised controlled trials in urology. <i>European Urology</i> , 2014 , 66, 1-3	10.2	10
218	Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study. <i>European Urology</i> , 2014 , 66, 489-99	10.2	156
217	Molecular subtyping of bladder cancer using Kohonen self-organizing maps. <i>Cancer Medicine</i> , 2014 , 3, 1225-34	4.8	14
216	BMP-regulated exosomes from Drosophila male reproductive glands reprogram female behavior. <i>Journal of Cell Biology</i> , 2014 , 206, 671-88	7.3	86
215	Training recruiters to randomized trials to facilitate recruitment and informed consent by exploring patients' treatment preferences. <i>Trials</i> , 2014 , 15, 323	2.8	41
214	A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. <i>Nature Genetics</i> , 2014 , 46, 1103-9	36.3	331
213	Prevention and early detection of prostate cancer. <i>Lancet Oncology</i> , 2014 , 15, e484-92	21.7	277
212	The importance of dietary change for men diagnosed with and at risk of prostate cancer: a multi-centre interview study with men, their partners and health professionals. <i>BMC Family Practice</i> , 2014 , 15, 81	2.6	30
211	Design and preliminary recruitment results of the Cluster randomised triAl of PSA testing for Prostate cancer (CAP). <i>British Journal of Cancer</i> , 2014 , 110, 2829-36	8.7	23
210	The intellectual challenges and emotional consequences of equipoise contributed to the fragility of recruitment in six randomized controlled trials. <i>Journal of Clinical Epidemiology</i> , 2014 , 67, 912-20	5.7	98
209	Reply to Behnam Shakiba's letter to the editor re: Philipp Dahm, James N'Dow, Lars Holmberg, Freddie Hamdy. The future of randomised controlled trials in urology. <i>Eur Urol</i> 2014 ;66:1-3. <i>European Urology</i> , 2014 , 66, e8	10.2	

208	Polymorphisms of an innate immune gene, toll-like receptor 4, and aggressive prostate cancer risk: a systematic review and meta-analysis. <i>PLoS ONE</i> , 2014 , 9, e110569	3.7	17
207	Fine-mapping the HOXB region detects common variants tagging a rare coding allele: evidence for synthetic association in prostate cancer. <i>PLoS Genetics</i> , 2014 , 10, e1004129	6	30
206	PROSPECTIV-a pilot trial of a nurse-led psychoeducational intervention delivered in primary care to prostate cancer survivors: study protocol for a randomised controlled trial. <i>BMJ Open</i> , 2014 , 4, e005186 ³		8
205	Estimating age and ethnic variation in the histological prevalence of prostate cancer to inform the impact of screening policies. <i>International Journal of Urology</i> , 2014 , 21, 786-92	2.3	9
204	Adherence to dietary and lifestyle recommendations and prostate cancer risk in the prostate testing for cancer and treatment (ProtecT) trial. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014 , 23, 2066-77	4	27
203	Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial. <i>Lancet Oncology</i> , 2014 , 15, 1109-18	21.7	157
202	Men's knowledge and attitudes towards dietary prevention of a prostate cancer diagnosis: a qualitative study. <i>BMC Cancer</i> , 2014 , 14, 812	4.8	13
201	Genetic variation in prostate-specific antigen-detected prostate cancer and the effect of control selection on genetic association studies. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014 , 23, 1356-1365 ⁴	1365	24
200	Evaluating the Prostate Cancer Prevention Trial High Grade Prostate Cancer Risk Calculator in 10 international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. <i>World Journal of Urology</i> , 2014 , 32, 185-91	4	23
199	Men with prostate cancer make positive dietary changes following diagnosis and treatment. <i>Cancer Causes and Control</i> , 2013 , 24, 1119-28	2.8	30
198	Common genetic variants associated with disease from genome-wide association studies are mutually exclusive in prostate cancer and rheumatoid arthritis. <i>BJU International</i> , 2013 , 111, 1148-55	5.6	7
197	DNA damage response in peritumoral regions of oesophageal cancer microenvironment. <i>Carcinogenesis</i> , 2013 , 34, 139-45	4.6	13
196	Very low PSA concentrations and deletions of the KLK3 gene. <i>Clinical Chemistry</i> , 2013 , 59, 234-44	5.5	10
195	Insulin-like growth factors (IGFs) and IGF-binding proteins in active monitoring of localized prostate cancer: a population-based observational study. <i>Cancer Causes and Control</i> , 2013 , 24, 39-45	2.8	8
194	Associations of adiponectin and leptin with stage and grade of PSA-detected prostate cancer: the ProtecT study. <i>Cancer Causes and Control</i> , 2013 , 24, 323-34	2.8	27
193	Transurethral resection biopsy as part of a saturation biopsy protocol: a cohort study and review of the literature. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013 , 31, 542-8	2.8	2
192	Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. <i>Nature Genetics</i> , 2013 , 45, 385-91, 391e1-2	36.3	413
191	Common variation in Kallikrein genes KLK5, KLK6, KLK12, and KLK13 and risk of prostate cancer and tumor aggressiveness. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013 , 31, 635-43	2.8	25

190	A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. <i>Human Molecular Genetics</i> , 2013 , 22, 408-15	5.6	109
189	Psychological impact of prostate biopsy: physical symptoms, anxiety, and depression. <i>Journal of Clinical Oncology</i> , 2013 , 31, 4235-41	2.2	60
188	A genome-wide association scan (GWAS) for mean telomere length within the COGS project: identified loci show little association with hormone-related cancer risk. <i>Human Molecular Genetics</i> , 2013 , 22, 5056-64	5.6	107
187	Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression. <i>Human Molecular Genetics</i> , 2013 , 22, 2520-8	5.6	88
186	Using genetic proxies for lifecourse sun exposure to assess the causal relationship of sun exposure with circulating vitamin d and prostate cancer risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013 , 22, 597-606	4	19
185	Associations of circulating 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and vitamin D pathway genes with prostate-specific antigen progression in men with localized prostate cancer undergoing active monitoring. <i>European Journal of Cancer Prevention</i> , 2013 , 22, 121-5	2	7
184	The emerging role of histone deacetylase (HDAC) inhibitors in urological cancers. <i>BJU International</i> , 2013 , 111, 537-42	5.6	32
183	Alcohol consumption and PSA-detected prostate cancer risk--a case-control nested in the ProtecT study. <i>International Journal of Cancer</i> , 2013 , 132, 2176-85	7.5	27
182	Current vaccination strategies for prostate cancer. <i>European Urology</i> , 2012 , 61, 290-306	10.2	26
181	Serum insulin-like growth factors and mortality in localised and advanced clinically detected prostate cancer. <i>Cancer Causes and Control</i> , 2012 , 23, 347-54	2.8	30
180	Evaluating genetic risk for prostate cancer among Japanese and Latinos. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012 , 21, 2048-58	4	46
179	A study based on whole-genome sequencing yields a rare variant at 8q24 associated with prostate cancer. <i>Nature Genetics</i> , 2012 , 44, 1326-9	36.3	151
178	Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. <i>World Journal of Urology</i> , 2012 , 30, 181-7	4	50
177	Associations of circulating retinol, vitamin E, and 1,25-dihydroxyvitamin D with prostate cancer diagnosis, stage, and grade. <i>Cancer Causes and Control</i> , 2012 , 23, 1865-73	2.8	19
176	Predictors of attendance for prostate-specific antigen screening tests and prostate biopsy. <i>European Urology</i> , 2012 , 62, 649-55	10.2	20
175	iTRAQ identification of candidate serum biomarkers associated with metastatic progression of human prostate cancer. <i>PLoS ONE</i> , 2012 , 7, e30885	3.7	48
174	Associations of circulating 25-hydroxyvitamin D with prostate cancer diagnosis, stage and grade. <i>International Journal of Cancer</i> , 2012 , 131, 1187-96	7.5	55
173	Mre11-dependent degradation of stalled DNA replication forks is prevented by BRCA2 and PARP1. <i>Cancer Research</i> , 2012 , 72, 2814-21	10.1	227

172	Predictors of 25-hydroxyvitamin D and its association with risk factors for prostate cancer: evidence from the prostate testing for cancer and treatment study. <i>Cancer Causes and Control</i> , 2012 , 23, 575-88	2.8	20
171	A cross-sectional analysis of the association between diet and insulin-like growth factor (IGF)-I, IGF-II, IGF-binding protein (IGFBP)-2, and IGFBP-3 in men in the United Kingdom. <i>Cancer Causes and Control</i> , 2012 , 23, 907-17	2.8	30
170	Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group. <i>World Journal of Urology</i> , 2012 , 30, 149-55	4	81
169	The handling and sampling of radical prostatectomy specimens for reporting and research: the Oxford approach. <i>Journal of Clinical Pathology</i> , 2012 , 65, 1057-61	3.9	8
168	Circulating insulin-like growth factors and IGF-binding proteins in PSA-detected prostate cancer: the large case-control study ProtecT. <i>Cancer Research</i> , 2012 , 72, 503-15	10.1	44
167	Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study. <i>BMJ, The</i> , 2012 , 344, d7894	5.9	163
166	Associations of lifestyle factors and anthropometric measures with repeat PSA levels during active surveillance/monitoring. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012 , 21, 1877-85	4	15
165	Flexible cystoscopy findings in patients investigated for profound lower urinary tract symptoms, recurrent urinary tract infection, and pain. <i>Journal of Endourology</i> , 2012 , 26, 1468-72	2.7	6
164	Bone morphogenetic protein- and mating-dependent secretory cell growth and migration in the Drosophila accessory gland. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 19292-7	11.5	35
163	Protease nexin 1 inhibits hedgehog signaling in prostate adenocarcinoma. <i>Journal of Clinical Investigation</i> , 2012 , 122, 4025-36	15.9	33
162	A germline variant in the TP53 polyadenylation signal confers cancer susceptibility. <i>Nature Genetics</i> , 2011 , 43, 1098-103	36.3	203
161	A Peer Review Intervention for Monitoring and Evaluating sites (PRIME) that improved randomized controlled trial conduct and performance. <i>Journal of Clinical Epidemiology</i> , 2011 , 64, 628-36	5.7	17
160	Exploring treatment preferences facilitated recruitment to randomized controlled trials. <i>Journal of Clinical Epidemiology</i> , 2011 , 64, 1127-36	5.7	73
159	Long-term quality of life in prostate cancer. <i>Lancet Oncology, The</i> , 2011 , 12, 832-3	21.7	2
158	Prostate-specific antigen testing rates remain low in UK general practice: a cross-sectional study in six English cities. <i>BJU International</i> , 2011 , 108, 1402-8	5.6	46
157	Seasonal variation in prostate-specific antigen levels: a large cross-sectional study of men in the UK. <i>BJU International</i> , 2011 , 108, 1409-14	5.6	6
156	Association of obesity with prostate cancer: a case-control study within the population-based PSA testing phase of the ProtecT study. <i>British Journal of Cancer</i> , 2011 , 104, 875-81	8.7	20
155	MicroRNA in prostate, bladder, and kidney cancer: a systematic review. <i>European Urology</i> , 2011 , 59, 671-80.2	10.2	355

154	Identification of a novel prostate cancer susceptibility variant in the KLK3 gene transcript. <i>Human Genetics</i> , 2011 , 129, 687-94	6.3	72
153	Association of diabetes mellitus with prostate cancer: nested case-control study (Prostate testing for cancer and treatment study). <i>International Journal of Cancer</i> , 2011 , 128, 440-6	7.5	53
152	Associations of aspirin, nonsteroidal anti-inflammatory drug and paracetamol use with PSA-detected prostate cancer: findings from a large, population-based, case-control study (the ProtecT study). <i>International Journal of Cancer</i> , 2011 , 128, 1442-8	7.5	35
151	PSA-detected prostate cancer and the potential for dedifferentiation--estimating the proportion capable of progression. <i>International Journal of Cancer</i> , 2011 , 128, 1462-70	7.5	13
150	Validation of a modelling approach for estimating the likely effectiveness of cancer screening using cancer data on prevalence screening and incidence. <i>Cancer Epidemiology</i> , 2011 , 35, 139-44	2.8	4
149	Acupuncture in urological practice--a survey of urologists in England. <i>Complementary Therapies in Medicine</i> , 2011 , 19, 27-31	3.5	8
148	Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. <i>Nature Genetics</i> , 2011 , 43, 785-91	36.3	243
147	Hypermethylation of CpG islands and shores around specific microRNAs and mirtrons is associated with the phenotype and presence of bladder cancer. <i>Clinical Cancer Research</i> , 2011 , 17, 1287-96	12.9	82
146	Use of macrophages to target therapeutic adenovirus to human prostate tumors. <i>Cancer Research</i> , 2011 , 71, 1805-15	10.1	90
145	Genome-wide association study identifies new prostate cancer susceptibility loci. <i>Human Molecular Genetics</i> , 2011 , 20, 3867-75	5.6	143
144	Curative radiation therapy in prostate cancer. <i>Acta Oncologica</i> , 2011 , 50 Suppl 1, 98-103	3.2	12
143	Suitability of PSA-detected localised prostate cancers for focal therapy: experience from the ProtecT study. <i>British Journal of Cancer</i> , 2011 , 105, 931-7	8.7	15
142	Association between Prostinogen (KLK15) genetic variants and prostate cancer risk and aggressiveness in Australia and a meta-analysis of GWAS data. <i>PLoS ONE</i> , 2011 , 6, e26527	3.7	11
141	The causal roles of vitamin B(12) and transcobalamin in prostate cancer: can Mendelian randomization analysis provide definitive answers?. <i>International Journal of Molecular Epidemiology and Genetics</i> , 2011 , 2, 316-27	0.9	9
140	Mutation analysis of the MSMB gene in familial prostate cancer. <i>British Journal of Cancer</i> , 2010 , 102, 4148-7	8.7	19
139	Impact of prostate cancer testing: an evaluation of the emotional consequences of a negative biopsy result. <i>British Journal of Cancer</i> , 2010 , 102, 1335-40	8.7	60
138	Genetic correction of PSA values using sequence variants associated with PSA levels. <i>Science Translational Medicine</i> , 2010 , 2, 62ra92	17.5	125
137	Androgen regulates ADAMTS15 gene expression in prostate cancer cells. <i>Cancer Investigation</i> , 2010 , 28, 698-710	2.1	10

136	Associations of folate, vitamin B12, homocysteine, and folate-pathway polymorphisms with prostate-specific antigen velocity in men with localized prostate cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010 , 19, 2833-8	4	20
135	The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group. <i>Clinical Cancer Research</i> , 2010 , 16, 4374-81	12.9	72
134	Targeting chemotherapy to advanced bladder cancer patients most likely to benefit. <i>Future Oncology</i> , 2010 , 6, 193-6	3.6	1
133	High aldehyde dehydrogenase activity identifies tumor-initiating and metastasis-initiating cells in human prostate cancer. <i>Cancer Research</i> , 2010 , 70, 5163-73	10.1	296
132	Circulating folate, vitamin B12, homocysteine, vitamin B12 transport proteins, and risk of prostate cancer: a case-control study, systematic review, and meta-analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010 , 19, 1632-42	4	116
131	The relation between adiposity throughout the life course and variation in IGFs and IGFBPs: evidence from the ProtecT (Prostate testing for cancer and Treatment) study. <i>Cancer Causes and Control</i> , 2010 , 21, 1829-42	2.8	23
130	Development of a new method for monitoring prostate-specific antigen changes in men with localised prostate cancer: a comparison of observational cohorts. <i>European Urology</i> , 2010 , 57, 446-52	10.2	12
129	The application of artificial intelligence to microarray data: identification of a novel gene signature to identify bladder cancer progression. <i>European Urology</i> , 2010 , 57, 398-406	10.2	34
128	Reply to Dennis Morrod's Letter to the Editor and Fritz H. Schröder's Reply to Dennis Morrod's Letter to the Editor re: Monique J. Roobol, Ewout W. Steyerberg, Ries Kranse, et al. A Risk-Based Strategy Improves Prostate-Specific Antigen-Driven Detection of Prostate Cancer. <i>Eur Urol</i> 2010 ;57:7985. <i>European Urology</i> , 2010 , 58, 329-330	10.2	
127	Word of wisdom. Re: mortality results from the Göteborg randomised population-based prostate-cancer screening trial. <i>European Urology</i> , 2010 , 58, 940-1	10.2	
126	Evaluation of the frequency of putative prostate cancer stem cells in primary and metastatic prostate cancer. <i>Prostate</i> , 2010 , 70, 875-82	4.2	54
125	Eight-plex iTRAQ analysis of variant metastatic human prostate cancer cells identifies candidate biomarkers of progression: An exploratory study. <i>Prostate</i> , 2010 , 70, 1313-32	4.2	38
124	Evaluation of association of HNF1B variants with diverse cancers: collaborative analysis of data from 19 genome-wide association studies. <i>PLoS ONE</i> , 2010 , 5, e10858	3.7	24
123	Associations between an obesity related genetic variant (FTO rs9939609) and prostate cancer risk. <i>PLoS ONE</i> , 2010 , 5, e13485	3.7	46
122	A polymorphism in the glucokinase gene that raises plasma fasting glucose, rs1799884, is associated with diabetes mellitus and prostate cancer: findings from a population-based, case-control study (the ProtecT study). <i>International Journal of Molecular Epidemiology and Genetics</i> , 2010 , 1, 175-83	0.9	11
121	Metabolic imbalance and prostate cancer progression. <i>International Journal of Molecular Epidemiology and Genetics</i> , 2010 , 1, 248-71	0.9	9
120	Neurofuzzy modeling to determine recurrence risk following radical cystectomy for nonmetastatic urothelial carcinoma of the bladder. <i>Clinical Cancer Research</i> , 2009 , 15, 3150-5	12.9	19
119	PTGS2-899G>C and prostate cancer risk: a population-based nested case-control study (ProtecT) and a systematic review with meta-analysis. <i>Prostate Cancer and Prostatic Diseases</i> , 2009 , 12, 296-300	6.2	15

118	Distinct microRNA alterations characterize high- and low-grade bladder cancer. <i>Cancer Research</i> , 2009 , 69, 8472-81	10.1	260
117	Mean sojourn time, overdiagnosis, and reduction in advanced stage prostate cancer due to screening with PSA: implications of sojourn time on screening. <i>British Journal of Cancer</i> , 2009 , 100, 1198-204	8.7	48
116	A recurrent truncating germline mutation in the BRIP1/FANCI gene and susceptibility to prostate cancer. <i>British Journal of Cancer</i> , 2009 , 100, 426-30	8.7	44
115	Feasibility and cost of obtaining informed consent for essential review of medical records in large-scale health services research. <i>Journal of Health Services Research and Policy</i> , 2009 , 14, 77-81	2.4	13
114	Stage shift in PSA-detected prostate cancers - effect modification by Gleason score. <i>Journal of Medical Screening</i> , 2009 , 16, 98-101	1.4	15
113	LYRIC/AEG-1 is targeted to different subcellular compartments by ubiquitylation and intrinsic nuclear localization signals. <i>Clinical Cancer Research</i> , 2009 , 15, 3003-13	12.9	67
112	Genetic variants in the vitamin d receptor are associated with advanced prostate cancer at diagnosis: findings from the prostate testing for cancer and treatment study and a systematic review. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009 , 18, 2874-81	4	60
111	Association of folate-pathway gene polymorphisms with the risk of prostate cancer: a population-based nested case-control study, systematic review, and meta-analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009 , 18, 2528-39	4	75
110	It's not just what you say, it's also how you say it: opening the 'black box' of informed consent appointments in randomised controlled trials. <i>Social Science and Medicine</i> , 2009 , 68, 2018-28	5.1	127
109	FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours. <i>European Urology</i> , 2009 , 55, 650-7	10.2	90
108	Life course sun exposure and risk of prostate cancer: population-based nested case-control study and meta-analysis. <i>International Journal of Cancer</i> , 2009 , 125, 1414-23	7.5	43
107	Prostate cancer proteomics: The urgent need for clinically validated biomarkers. <i>Proteomics - Clinical Applications</i> , 2009 , 3, 197-212	3.1	7
106	Identification of new genetic risk factors for prostate cancer. <i>Asian Journal of Andrology</i> , 2009 , 11, 49-55	2.8	20
105	Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. <i>Nature Genetics</i> , 2009 , 41, 1116-21	36.3	360
104	Multiple loci on 8q24 associated with prostate cancer susceptibility. <i>Nature Genetics</i> , 2009 , 41, 1058-60	36.3	252
103	Current strategies for monitoring men with localised prostate cancer lack a strong evidence base: observational longitudinal study. <i>British Journal of Cancer</i> , 2009 , 101, 390-4	8.7	15
102	Population-based prostate-specific antigen testing in the UK leads to a stage migration of prostate cancer. <i>BJU International</i> , 2009 , 104, 1592-8	5.6	63
101	Do the risk factors of age, family history of prostate cancer or a higher prostate specific antigen level raise anxiety at prostate biopsy?. <i>European Journal of Cancer</i> , 2009 , 45, 2569-73	7.5	15

100	Associations of sexual dysfunction symptoms with PSA-detected localised and advanced prostate cancer: a case-control study nested within the UK population-based ProtecT (Prostate testing for cancer and Treatment) study. <i>European Journal of Cancer</i> , 2009 , 45, 3254-61	7.5	9
99	Psychological distress and prostate specific antigen levels in men with and without prostate cancer. <i>Brain, Behavior, and Immunity</i> , 2009 , 23, 1073-8	16.6	6
98	Development of a complex intervention improved randomization and informed consent in a randomized controlled trial. <i>Journal of Clinical Epidemiology</i> , 2009 , 62, 29-36	5.7	121
97	Factors distinguishing general practitioners who more readily participated in a large randomized trial were identified. <i>Journal of Clinical Epidemiology</i> , 2009 , 62, 67-73	5.7	11
96	Screening for prostate cancer remains controversial. <i>Lancet, The</i> , 2009 , 374, 1482-3	40	19
95	Trends in Prostate Cancer Screening: Overview of the UK 2009 , 15-21		3
94	Prostate cancer cells home to bone in a new in vivo model of bone metastasis. <i>FASEB Journal</i> , 2009 , 23, 927.11	0.9	1
93	Multiple newly identified loci associated with prostate cancer susceptibility. <i>Nature Genetics</i> , 2008 , 40, 316-21	36.3	722
92	Secular trends in prostate cancer mortality, incidence and treatment: England and Wales, 1975-2004. <i>BJU International</i> , 2008 , 101, 547-55	5.6	44
91	A comparison of the performance of microsatellite and methylation urine analysis for predicting the recurrence of urothelial cell carcinoma, and definition of a set of markers by Bayesian network analysis. <i>BJU International</i> , 2008 , 101, 1448-53	5.6	44
90	Associations of lower urinary tract symptoms with prostate-specific antigen levels, and screen-detected localized and advanced prostate cancer: a case-control study nested within the UK population-based ProtecT (Prostate testing for cancer and Treatment) study. <i>BJU International</i> , 2008 , 102, 1400-6	5.6	26
89	Prostate-specific antigen testing and prostate biopsy: are self-reported lower urinary tract symptoms and health-related quality of life associated with the decision to undergo these investigations?. <i>BJU International</i> , 2008 , 102, 1629-33	5.6	10
88	Decision-making about PSA testing and prostate biopsies: a qualitative study embedded in a primary care randomised trial. <i>European Urology</i> , 2008 , 53, 1186-93	10.2	38
87	Screening for prostate cancer: an update. <i>European Urology</i> , 2008 , 53, 37-44	10.2	30
86	Contribution of a single repeat PSA test to prostate cancer risk assessment: experience from the ProtecT study. <i>European Urology</i> , 2008 , 53, 777-84	10.2	16
85	iTRAQ-facilitated proteomic analysis of human prostate cancer cells identifies proteins associated with progression. <i>Journal of Proteome Research</i> , 2008 , 7, 897-907	5.6	95
84	Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study. <i>Lancet Oncology, The</i> , 2008 , 9, 445-52	21.7	192
83	What are the practitioner-level determinants for inappropriate PSA testing?. <i>Nature Reviews Urology</i> , 2008 , 5, 70-1		

82	Low risk research using routinely collected identifiable health information without informed consent: encounters with the Patient Information Advisory Group. <i>Journal of Medical Ethics</i> , 2008 , 34, 37-40	2.5	16
81	Multiple novel prostate cancer predisposition loci confirmed by an international study: the PRACTICAL Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008 , 17, 2052-61	4	134
80	Height and prostate cancer risk: a large nested case-control study (ProtecT) and meta-analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008 , 17, 2325-36	4	80
79	Multiple loci with different cancer specificities within the 8q24 gene desert. <i>Journal of the National Cancer Institute</i> , 2008 , 100, 962-6	9.7	283
78	The spectrum of prostate cancer care: From curative intent to palliation. <i>Current Prostate Reports</i> , 2008 , 6, 56-63		
77	Promoter methylation correlates with reduced Smad4 expression in advanced prostate cancer. <i>Prostate</i> , 2008 , 68, 661-74	4.2	46
76	Promoter hypermethylation in circulating blood cells identifies prostate cancer progression. <i>International Journal of Cancer</i> , 2008 , 122, 952-6	7.5	66
75	Similar treatment outcomes for radical cystectomy and radical radiotherapy in invasive bladder cancer treated at a United Kingdom specialist treatment center: in regard to Kotwal et al. (Int J Radiat Oncol Biol Phys 2008;70:456-463). <i>International Journal of Radiation Oncology Biology Physics</i> , 2008 , 71, 1681-2, author reply 1682	4	1
74	Epidemiology, Pathology and Pathogenesis 2008 , 451-469		
73	Application of artificial intelligence to the management of urological cancer. <i>Journal of Urology</i> , 2007 , 178, 1150-6	2.5	69
72	The antibody MAB8051 directed against osteoprotegerin detects carbonic anhydrase II: implications for association studies with human cancers. <i>International Journal of Cancer</i> , 2007 , 121, 1958-66	7.5	4
71	DNA methylation and immunohistochemical analysis of the S100A4 calcium binding protein in human prostate cancer. <i>Prostate</i> , 2007 , 67, 341-7	4.2	15
70	Human prostate cancer cells express neuroendocrine cell markers PGP 9.5 and chromogranin A. <i>Prostate</i> , 2007 , 67, 1761-9	4.2	46
69	Clinically localised prostate cancer is microsatellite stable. <i>BJU International</i> , 2007 , 99, 1031-5	5.6	12
68	The impact of reducing the prostate-specific antigen threshold and including isoform reflex tests on the performance characteristics of a prostate-cancer detection programme. <i>BJU International</i> , 2007 , 100, 514-7	5.6	9
67	Combination of polymorphisms from genes related to estrogen metabolism and risk of prostate cancers: the hidden face of estrogens. <i>Journal of Clinical Oncology</i> , 2007 , 25, 3596-602	2.2	83
66	The spectrum of prostate cancer care: from curative intent to palliation. <i>Current Urology Reports</i> , 2007 , 8, 245-52	2.9	4
65	Phenol sulfotransferase SULT1A1*2 allele and enhanced risk of upper urinary tract urothelial cell carcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007 , 16, 2500-3	4	17

64	Gene expression assays. <i>Advances in Clinical Chemistry</i> , 2007 , 44, 247-92	5.8	30
63	Molecular detection of localized prostate cancer using quantitative methylation-specific PCR on urinary cells obtained following prostate massage. <i>Clinical Cancer Research</i> , 2007 , 13, 1720-5	12.9	126
62	Promoter hypermethylation identifies progression risk in bladder cancer. <i>Clinical Cancer Research</i> , 2007 , 13, 2046-53	12.9	150
61	Detection of prostate cancer in unselected young men: prospective cohort nested within a randomised controlled trial. <i>BMJ, The</i> , 2007 , 335, 1139	5.9	16
60	Lack of noggin expression by cancer cells is a determinant of the osteoblast response in bone metastases. <i>American Journal of Pathology</i> , 2007 , 170, 160-75	5.8	85
59	Re: Incidence of Initial Local Therapy Among Men with Lower-Risk Prostate Cancer in the United States. <i>European Urology</i> , 2006 , 50, 1368-1370	10.2	
58	A model of the natural history of screen-detected prostate cancer. <i>British Journal of Cancer</i> , 2006 , 95, 1122-3	8.7	3
57	Continuing controversy over monitoring men with localized prostate cancer: a systematic review of programs in the prostate specific antigen era. <i>Journal of Urology</i> , 2006 , 176, 439-49	2.5	40
56	Neuro-fuzzy modeling: an accurate and interpretable method for predicting bladder cancer progression. <i>Journal of Urology</i> , 2006 , 175, 474-9	2.5	27
55	Multifocal urothelial cancers with the mutator phenotype are of monoclonal origin and require panurothelial treatment for tumor clearance. <i>Journal of Urology</i> , 2006 , 175, 2323-30	2.5	51
54	A comparison of socio-demographic and psychological factors between patients consenting to randomisation and those selecting treatment (the ProtecT study). <i>Contemporary Clinical Trials</i> , 2006 , 27, 413-9	2.3	19
53	Measuring the psychosocial impact of population-based prostate-specific antigen testing for prostate cancer in the UK. <i>BJU International</i> , 2006 , 98, 777-82	5.6	35
52	Bone-Directed Therapy in Prostate Cancer: Rationale and Novel Approaches. <i>Translational Medicine Series</i> , 2006 , 223-236		
51	472: The Value of Repeat Serum PSA Measurements in the Detection of Prostate Cancer - Experience from the Feasibility Phase of the UK ProtecT Study. <i>Journal of Urology</i> , 2006 , 175, 153-153	2.5	2
50	The Use of Proteomics in Urological Research. <i>EAU Update Series</i> , 2005 , 3, 171-179		5
49	The Role of Genetic Instability in the Pathogenesis and Progression of Urothelial Carcinoma. <i>EAU Update Series</i> , 2005 , 3, 180-188		
48	Microsatellite instability as predictor of survival in patients with invasive upper urinary tract transitional cell carcinoma. <i>Urology</i> , 2005 , 65, 1233-7	1.6	61
47	Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis. <i>European Urology</i> , 2005 , 48, 386-99; discussion 398-9	10.2	183

46	Promoter hyper-methylation of calcium binding proteins S100A6 and S100A2 in human prostate cancer. <i>Prostate</i> , 2005 , 65, 322-30	4.2	43
45	Screening for Prostate Cancer 2005 , 31-40		
44	Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. <i>Journal of Clinical Oncology</i> , 2005 , 23, 2903-10	2.2	249
43	Prognostic value of serum markers for prostate cancer. <i>Scandinavian Journal of Urology and Nephrology</i> , 2005 , 64-81		55
42	Do height-related variations in insulin-like growth factors underlie the associations of stature with adult chronic disease?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 213-8	5.6	46
41	Serum insulin-like growth factor-I is positively associated with serum prostate-specific antigen in middle-aged men without evidence of prostate cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2004 , 13, 163-5	4	18
40	Evaluation of the clinical benefit of permixon and tamsulosin in severe BPH patients-PERMA study subset analysis. <i>European Urology</i> , 2004 , 45, 773-9; discussion 779-80	10.2	50
39	Human bone marrow stromal cells protect prostate cancer cells from TRAIL-induced apoptosis. <i>Journal of Bone and Mineral Research</i> , 2004 , 19, 1712-21	6.3	43
38	Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer. <i>Prostate</i> , 2004 , 59, 304-10	4.2	50
37	Screen-detected prostate cancer and the insulin-like growth factor axis: results of a population-based case-control study. <i>International Journal of Cancer</i> , 2004 , 108, 887-92	7.5	47
36	Measurement of insulin-like growth factor axis does not enhance specificity of PSA-based prostate cancer screening. <i>Urology</i> , 2004 , 64, 317-22	1.6	9
35	Dysregulated expression of S100A11 (calgizzarin) in prostate cancer and precursor lesions. <i>Human Pathology</i> , 2004 , 35, 1385-91	3.7	59
34	Less is more: artificial intelligence and gene-expression arrays. <i>Lancet, The</i> , 2004 , 364, 2003-4	4.0	6
33	Are diet-prostate cancer associations mediated by the IGF axis? A cross-sectional analysis of diet, IGF-I and IGFBP-3 in healthy middle-aged men. <i>British Journal of Cancer</i> , 2003 , 88, 1682-6	8.7	111
32	Ethics of clinical trials from bayesian perspective: randomisation to clinical trials may solve dilemma of treatment choice in prostate cancer. <i>BMJ, The</i> , 2003 , 326, 1456	5.9	2
31	The survival effect of prolactin on PC3 prostate cancer cells. <i>European Urology</i> , 2003 , 43, 301-8	10.2	33
30	Perceptions of equipoise are crucial to trial participation: a qualitative study of men in the ProtecT study. <i>Contemporary Clinical Trials</i> , 2003 , 24, 272-82		106
29	Differential expression of hMLH1 and hMSH2 is related to bladder cancer grade, stage and prognosis but not microsatellite instability. <i>International Journal of Cancer</i> , 2003 , 105, 484-90	7.5	64

28	Recent trends in the use of radical prostatectomy in England: the epidemiology of diffusion. <i>BJU International</i> , 2003 , 91, 331-6; discussion 336	5.6	42
27	Distinct patterns of microsatellite instability are seen in tumours of the urinary tract. <i>Oncogene</i> , 2003 , 22, 8699-706	9.2	113
26	Endothelin and Skeletal Metastases in Hormone-Refractory Prostate Cancer. <i>European Urology Supplements</i> , 2003 , 2, 15-19	0.9	1
25	Early diagnosis and surgical management of prostate cancer. <i>Cancer Treatment Reviews</i> , 2003 , 29, 151-60	4.4	19
24	Who can best recruit to randomized trials? Randomized trial comparing surgeons and nurses recruiting patients to a trial of treatments for localized prostate cancer (the ProtecT study). <i>Journal of Clinical Epidemiology</i> , 2003 , 56, 605-9	5.7	62
23	The Molecular Staging of Prostate Cancer 2003 , 793-809		
22	Artificial intelligence in predicting bladder cancer outcome: a comparison of neuro-fuzzy modeling and artificial neural networks. <i>Clinical Cancer Research</i> , 2003 , 9, 4172-7	12.9	59
21	Comparison of a Phytotherapeutic Agent (Permixon) with an α -Blocker (Tamsulosin) in the Treatment of Benign Prostatic Hyperplasia: A 1-Year Randomized International Study. <i>European Urology</i> , 2002 , 41, 497-507	10.2	107
20	Staging in prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2002 , 2, 48-58	3.5	
19	Quality improvement report: Improving design and conduct of randomised trials by embedding them in qualitative research: ProtecT (prostate testing for cancer and treatment) study. Commentary: presenting unbiased information to patients can be difficult. <i>BMJ, The</i> , 2002 , 325, 766-70	5.9	388
18	Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. <i>Cancer Research</i> , 2002 , 62, 1619-23	10.1	182
17	Localization and quantification of mRNA for matrix metalloproteinase-2 (MMP-2) and tissue inhibitor of matrix metalloproteinase-2 (TIMP-2) in human benign and malignant prostatic tissue. <i>Prostate</i> , 2000 , 42, 18-25	4.2	52
16	NEURAL NETWORK ANALYSIS OF CLINICOPATHOLOGICAL AND MOLECULAR MARKERS IN BLADDER CANCER. <i>Journal of Urology</i> , 2000 , 163, 630-633	2.5	45
15	STAGING OF PROSTATE CANCER USING 3-DIMENSIONAL TRANSRECTAL ULTRASOUND IMAGES: A PILOT STUDY. <i>Journal of Urology</i> , 1999 , 162, 1318-1321	2.5	24
14	The immunohistochemical detection of cripto-1 in benign and malignant human bladder. <i>Journal of Pathology</i> , 1998 , 185, 108-11	9.4	9
13	Expression of Bcl-2, Bax, and p53 in high-grade prostatic intraepithelial neoplasia and localized prostate cancer: relationship with apoptosis and proliferation. <i>Prostate</i> , 1998 , 37, 223-9	4.2	68
12	The use of flow cytometry and RT-PCR in the detection of circulating PSA-positive cells in prostate cancer. <i>Methods in Molecular Biology</i> , 1998 , 92, 215-25	1.4	4
11	Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients. <i>Prostate</i> , 1996 , 29, 231-40; discussion 241-2	4.2	228

10	Comparison of phytotherapy (Permixon®) with finasteride in the treatment of benign prostate hyperplasia: A randomized international study of 1,098 patients 1996 , 29, 231		1
9	Comparison of phytotherapy (Permixon®) with finasteride in the treatment of benign prostate hyperplasia: A randomized international study of 1,098 patients 1996 , 29, 231		9
8	Transrectal ultrasound guided needle electromyography of the urethral sphincter in males. <i>Neurourology and Urodynamics</i> , 1995 , 14, 359-63	2.3	4
7	Safety and exceptional immunogenicity of novel 5T4 viral vectored vaccination regimes in early stage prostate cancer: a phase I clinical trial		1
6	Anti-androgens induce Rab11a-exosome secretion in prostate cancer by suppressing amino acid-sensitive PAT4-mTORC1 signalling		1
5	Systematic Review and Meta-Analysis of the Associations Between Body Mass Index, Prostate Cancer, Advanced Prostate Cancer and Prostate Specific Antigen		1
4	Glutamine Deprivation Regulates the Origin and Function of Cancer Cell Exosomes		3
3	A genetic risk score to guide age-specific, personalized prostate cancer screening		1
2	Polygenic hazard score is associated with prostate cancer in multi-ethnic populations		1
1	Mating Induces Switch From Hormone-Dependent to Independent Steroid Receptor-Mediated Growth in <i>Drosophila</i> Prostate-Like Cells		1